Skip to content

Serotonin: all studies

Page 12 of 400: studies 111 to 120 of 3,999, newest first. Back to the serotonin overview

Research

Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward.

Nature Communications November 20, 2025 Alaina M Jaster, Thomas M Hadlock, Belle Buzzi et al. 9 citations

Emerging evidence suggests that classical psychedelics may offer therapeutic potential for opioid use disorder (OUD) by alleviating key hallmarks such as altered reward processing and dependence. However, the mechanisms behind these effects remain unclear. Our data demonstrate that a single administration of the psychedelic psilocybin (PSI) reduces conditioned behavior and withdrawal induced by...

The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents

Molecular Psychiatry November 14, 2025 Núria Nadal‐gratacós, Pol Puigseslloses, Laura Hernández‐guzmán et al.

Psychedelics have garnered significant interest for their therapeutic potential in mental health conditions such as depression, anxiety, and post-traumatic stress disorder. While research has primarily focused on well-studied psychedelics, phenethylamine derivatives have also gathered interest for their potential therapeutic applications. Thus, this study aims to investigate the pharmacological...

DOI: 10.1038/s41380-025-03341-1 (opens in new tab) Full text (opens in new tab) Phenethylamine Antidepressant Dopamine Reboxetine +8

Ibogalogs improve spatial and recognition memory in rodents through a mechanism involving 5-HT2A receptor activation-enhanced NMDA receptor activity in hippocampal pyramidal CA1 neurons

Biomedicine & Pharmacotherapy November 13, 2025 Abdeslam Chagraoui, Luis A Haro Santillan, Renata Bocian et al. 5 citations

This study evaluated the effects of ibogalogs on recognition and spatial memory in rodents, focusing on potential hippocampal mechanisms. The Barnes maze study demonstrated that ibogaminalog (DM506) and ibogainalog (IBG) improved short- (30 min) and long-term (24 and 72 h) spatial memory in mice, whereas tabernanthalog (TBG) showed less efficacy. The novel object recognition task (NORT) results...

DOI: 10.1016/j.biopha.2025.118742 (opens in new tab) Hippocampal formation Nmda receptor Hippocampus Glutamate receptor +9

Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control.

ACS Medicinal Chemistry Letters November 10, 2025 Anna C. Renner, Robert B. Kargbo

High Resolution Image Download MS PowerPoint Slide Recent patents unveil a new wave of psychedelic analogs optimized for 5-HT 2 A receptor modulation, reduced adverse effects, and tunable duration of action. By refining DMT and psilocin scaffolds through prodrug design, fluorination, and structure–activity exploration, these innovations promise safer, shorter-acting psychedelic medicines that...

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

European Neuropsychopharmacology November 7, 2025 Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al. 12 citations

Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...

DOI: 10.1016/j.euroneuro.2025.09.011 (opens in new tab) Psychedelic therapy MDMA Therapy Psychedelic medicine Entheogenic therapy +12

The 4-alkyl chain length of 2,5-dimethoxyamphetamines differentially affects in vitro serotonin receptor actions versus in vivo psychedelic-like effects

Molecular Psychiatry November 5, 2025 Dino Luethi, Grant C. Glatfelter, Eline Pottie et al. 1 citation

Abstract Various ring-substituted α-methylphenethylamines (i.e., amphetamines) produce psychedelic-like effects that are primarily mediated by activity at 5-hydroxytryptamine 2A (5-HT 2A ) receptors. Small lipophilic substituents at the 4-position of the 2,5-dimethoxyamphetamine core structure can greatly enhance the clinical potency of such derivatives. Here, we studied the effects of various...

CNSC-36. PSILOCYBIN INDUCES SUSTAINED GLIOMA GROWTH THROUGH SEROTONERGIC AND TRKB PATHWAYS

Neuro-Oncology November 1, 2025 Richard Drexler, Belgin Yalçın, Rebecca Mancusi et al.

Abstract High-grade gliomas are the most aggressive form of brain tumors, and neuronal activity has emerged as a driver of glioma pathophysiology. Activity-dependent glioma growth results from paracrine factor signaling and bona fide neuron-to-glioma synapses that integrate glioma cells into brain-wide neuronal circuits. Here, we report how glioma cells integrate into serotonergic (5-HT)...

Novel Psilocin Derivatives as Serotonergic Psychedelic Agents for Treating CNS Disorders

ACS Medicinal Chemistry Letters October 22, 2025 Ram W. Sabnis

High Resolution Image Download MS PowerPoint Slide Provided herein are novel psilocin derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating central nervous system (CNS) disorders, and processes for preparing such compounds.

Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities

Brain October 19, 2025 Rebecca C Coray, Vincent Beliveau, Josua Zimmermann et al. 1 citation

Regular recreational use of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") has been consistently linked to verbal memory dysfunctions, whose neurobiological origins remain unclear. Although neurochemical, structural, and functional alterations resulting from repeated MDMA intake have been identified in user populations, only limited knowledge exists regarding potential interrelationships...

A novel psychedelic 5-HT 2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer

Journal of Psychopharmacology October 16, 2025 Gerard J. Marek, Soma Makai‐bölöni, Daniel Umbricht et al. 2 citations

Background: The treatment of major depressive disorder (MDD) with available antidepressant drugs is characterized by considerable ineffectiveness. Classical psychedelics such as psilocybin and N,N-dimethyltryptamine (DMT), which act primarily as 5-hydroxytryptamine 2A (5-HT 2A ) receptor agonists, have shown preliminary efficacy for inducing long-term remission in MDD after one or two doses....